Geneoscopy's New FDA-Approved Stool Collection Method Simplifies At-Home Colorectal Cancer Screening
'We've taken a critical step toward improving the at-home colorectal cancer screening experience by removing one of the most burdensome aspects for patients—the scraping of stool,' said Dr. Erica Barnell, Chief Medical & Science Officer of Geneoscopy. 'The new collection kit simplifies the process for collecting a patient's stool sample. By eliminating the most confusing and undesirable step, we believe ColoSense will drive higher adherence and better outcomes.'
ColoSense is indicated for individuals aged 45 and older who are at average risk for CRC. It uses advanced RNA technology to detect biomarkers associated with CRC and advanced adenomas (AA)—precancerous growths that can develop into cancer if left untreated. As the only FDA-approved RNA-based test for CRC screening, ColoSense demonstrated 93% sensitivity for CRC and 45% sensitivity for AA in average-risk individuals. Among average-risk individuals aged 45 to 49, where CRC incidence is on the rise, the test demonstrated 100% sensitivity for CRC and 44% sensitivity for AA.*
Despite the availability of multiple screening options, an estimated 44 million people aged 45-75 remain unscreened for CRC. 2 To help address a common barrier to stool-based screening, the updated ColoSense collection kit removes the need to scrape the sample. This improvement is expected to increase patient compliance, lower the rate of collection errors, and reduce the frequency of invalid samples. This ease of use can translate into fewer missed screenings and a greater overall impact on population health.
'To exceed 80% compliance for colorectal cancer screening, the patient experience for stool-based screening must be improved,' said Andrew Barnell, Chief Executive Officer of Geneoscopy. 'The new ColoSense test does that, offering patients everything they like about at-home, high-sensitivity screening, but now, with an easier collection process.'
ColoSense is included in National Comprehensive Cancer Network (NCCN) guidelines, based on an evaluation of the strength of its clinical evidence and the robust science behind the technology. The test will be available through Geneoscopy's strategic collaboration with Labcorp, expanding access for providers and patients across the United States. ColoSense represents a significant advancement in noninvasive stool testing options, reinforcing the importance of accessible tools that help reach individuals who are less likely to undergo colonoscopy.
About ColoSense
ColoSense is intended for the qualitative detection of colorectal neoplasia-associated RNA markers and for the presence of occult hemoglobin in human stool. ColoSense is for use with the ColoSense Collection Kit, the ColoSense Test Kit, the ColoSense Software, and the following instruments: Polymedco iFOBT Analyzer; bioMérieux EMAG Nucleic Acid Extraction System; and Bio-Rad QXDx ddPCR System. ColoSense is a single-site test performed at Geneoscopy, Inc.
A positive ColoSense result may indicate the presence of colorectal cancer (CRC), advanced adenomas (AA), or serrated precancerous lesions (SPL) and should be followed by a colonoscopy. ColoSense is indicated as a screening test for adults aged 45 years or older who are at the typical average risk for developing CRC. ColoSense is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals.
Results from Geneoscopy's pivotal CRC-PREVENT trial were published in The Journal of the American Medical Association (JAMA). For more information, visit www.colosense.com.
About Geneoscopy, Inc.
Geneoscopy, Inc. is a life sciences company focused on developing diagnostic tests for gastrointestinal health. Leveraging its proprietary, patented stool-derived eukaryotic RNA (seRNA) biomarker platform, Geneoscopy's mission is to empower patients and providers to transform gastrointestinal health through innovative diagnostics. The company's FDA-approved ColoSense test uses a proprietary RNA-based platform to screen for colorectal cancer and advanced adenomas for average-risk individuals over the age of 45. In partnership with leading universities and biopharmaceutical companies, Geneoscopy is also developing diagnostic tests for treatment selection and therapy monitoring in other areas of gastrointestinal health. For more information, visit www.geneoscopy.com and follow the company on LinkedIn.
References
Luque JS, Wallace K, Blankenship BF, et al. Formative Research on Knowledge and Preferences for Stool-based Tests compared to Colonoscopy: What Patients and Providers Think. J Community Health. 2018;43(6):1085-1092. doi:10.1007/s10900-018-0525-x
Hyams T, Mueller N, Curbow B, et al. Screening for colorectal cancer in people ages 45–49: research gaps, challenges and future directions for research and practice, Transl. Behav. Med, Volume 12, Issue 2, Feb 2022, Pages 198–202. https://doi.org/10.1093/tbm/ibab079
*ColoSense identified 5/5 colorectal cancers and 37/84 advanced adenomas.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
15 minutes ago
- Business Wire
Nanoco Reorganizes R&D and Invests in New Technology Resources for Next Chapter of Growth
RUNCORN, England--(BUSINESS WIRE)--Nanoco Group plc (LSE: NANO), a world leader in the development and manufacture of quantum dots and other nanomaterials emanating from its technology platform, announces the appointment of a new Director of Technology, alongside new investments in its R&D organization, concurrent with upcoming retirement of its Founder and CTO. Retirement of Dr. Nigel Pickett Dr. Nigel Pickett, Nanoco's founder, CTO and board member, has announced his pending retirement, effective August 19, 2025. Over the next six months, he will focus on long-term technology initiatives and will transition into an advisory role by February 2026. Nigel co-founded Nanoco in 2000 and has worked with the company from a small startup affiliated with University of Manchester, to a recognized leader in Quantum Dot (QD) technology, a vibrant organization with 350 patents making significant contributions to commercial applications of QDs in industries as diverse as Display, Image Sensor, Lighting, and Photovoltaic, among others. Jalal Bagherli, CBE, Nanoco's Chairman of the Board, commented: ' Nigel has made a significant contribution to Nanoco since its founding – the company was his life for the last quarter century. Because of Nigel's resourcefulness and ingenuity, Nanoco is now a leader in its field. We wish Nigel all the best in his well-deserved retirement.' Nanoco's Technology leadership Concurrent with Dr. Pickett's retirement, Nanoco announced several promotions in its R&D organization. Dr. Ombretta Masala, previously serving as Section Head, Nanomaterials, is assuming the role of Director of Technology, reporting to Nanoco's CEO Dmitry Shashkov. Dr. Masala has worked with Nanoco for nearly 20 years. In recognition of his outstanding technical expertise, Dr. James Harris has expanded his current role to become Head of QD Technologies. Dr. Parthiban Ramasamy has been promoted to the position of Lead Scientist, focusing his work on Image Sensor development. Dmitry Shashkov, Nanoco's CEO, commented: 'Under Nigel's leadership, the next generation of technology leaders have grown within the Company who are ready to lead Nanoco's Technology team through our next chapter of growth. With significant experience, Ombretta is the right person for the job. Since the launch of our new strategy in October, Nanoco has formed and strengthened several technical collaborations, all stemming from our strong reputation for QD technology development. I want to congratulate Ombretta, James and Parthiban with their expanded roles.' Investment in additional Technology resources Nanoco also announced several new hires into its R&D organization, further strengthening its technology talent base. Dr. Teoman Taskesen has joined Nanoco as Device Physicist. Teo joins the company after his previous 5-year tenure at Oxford Photovoltaics. Prior to that, he has had a successful international career in both academic and industrial settings related to Semiconductors, Quantum Dots and Photovoltaics (PV) in Turkey, Estonia and Germany. Dr. Rounak Naphade has joined Nanoco as Senior Chemist. Rounak comes to the company from University of Chicago, where for the last two years he worked on Quantum Dot (QD) development for infrared image sensors in the world-renowned lab of Prof. Philippe Guyot-Sionnest. Prior to University of Chicago, Rounak conducted doctoral and post-doctoral QD research in well-known academic centers in Saudi Arabia and India. Dr. Asim Önal has also joined the company as Senior Chemist. Asim comes to Nanoco after completing his PhD in Koc University in Istanbul, where he focused on development of QDs for Lighting, Display, and Biomedical applications. Prior to his PhD, Asim completed more than 5 years of undergraduate and graduate-level QD research in Turkey and Germany. Dr. Ombretta Masala, Nanoco's newly appointed Director of Technology, commented: 'We welcome Teo, Rounak, and Asim to Nanoco. Our growth and our reputation as a company depend on our team. All of our new hires come from distinguished technical backgrounds and bring their unique expertise to the company – we are delighted to expand our technology team with such strong, international talent.' Notes for editors: About Nanoco Group plc Nanoco (LSE: NANO) is a nanomaterial production and licensing group, specialising in the production of its patented cadmium free quantum dots (CFQD® materials) and other patented nanomaterials for use in the electronics industries. Founded in 2001 and headquartered in Runcorn, UK, Nanoco continues to build out a world-class, patent-protected IP portfolio alongside its existing scaled up production facilities for commercial orders. Nanomaterials are materials with dimensions typically in the range 1 - 100 nm. Nanomaterials have a range of useful properties, including optical and electronic. Quantum dots are a subclass of nanomaterial that have size-dependent optical and electronic properties. Within the sphere of quantum dots, the Group exploits different characteristics of the quantum dots to target different performance criteria that are attractive to specific markets or end-user applications such as the Sensor, Electronics and Display markets. Nanoco's CFQD® quantum dots are free of cadmium and other toxic heavy metals, and can be tuned to emit light at different wavelengths across the visible and infrared spectrum, rendering them useful for a wide range of display applications. Nanoco's HEATWAVE® quantum dots can be tuned to absorb light at different wavelengths across the near-infrared spectra, rendering them useful for applications including cameras and image sensors. Nanoco is listed on the Main Market of the London Stock Exchange, holds the LSE's Green Economy Mark, and trades under the ticker symbol NANO. For further information please visit:
Business Wire
15 minutes ago
- Business Wire
Jackson Healthcare Named to PEOPLE Companies That Care List for Second Consecutive Year
ATLANTA--(BUSINESS WIRE)-- Jackson Healthcare ®, one of the nation's premier providers of healthcare workforce services, today announced its second consecutive appearance on the PEOPLE ® Companies that Care list published by PEOPLE and Great Place To Work ®. This distinction highlights and celebrates businesses that lead with care for their people, local communities and the world. 'Being named again to the PEOPLE Companies that Care list is a testament to our deeply rooted company mission and values,' said Shane Jackson, president of Jackson Healthcare. 'One of our core values, Others First, guides us in putting people at the center of everything we do. We prioritize caring for our team and empowering them to make a meaningful impact through their work.' 'This recognition also reflects our deep commitment to providing a hand up in the communities in which we live, work and serve,' added Jackson. 'Through our LoveLifts community impact platform, we partner with over 450 nonprofit organizations worldwide to improve access to healthcare and enhance the wellbeing of young people. This recognition from PEOPLE and Great Place To Work honors the passion and purpose of our people within our organization and beyond, and I could not be more proud.' 'Businesses are vital pillars in the communities where they operate,' stated Michael C. Bush, CEO of Great Place To Work ®. 'Caring for your people and your community isn't something you do after you build a successful business; it's how to make your business successful.' The PEOPLE Companies that Care list is compiled using data from the Great Place To Work Trust Index ™ Survey, which measures whether all employees have a consistently positive experience at work, regardless of background or role. Companies that earn this recognition also submit a narrative with qualitative and quantitative insights to provide a complete picture of how their organizations care for their employees, communities and planet. To be considered for the list, companies must also be Great Place To Work ® Certified ™. 'Witnessing the innovative spirit with which these companies invest in their employees, communities and the world is truly invigorating,' added Charlotte Triggs, PEOPLE GM and editor-in-chief. 'Their commitment reflects our mission, to feature what happens when ordinary people do extraordinary work.' In addition to being on the 2025 PEOPLE Companies that Care list, Jackson Healthcare is on the 2025 Fortune 100 Best Companies to Work For ® list, as well as it's most recent Best Workplaces for Women ™ and Best Workplaces in Health Care ™ lists. The organization has also been Great Place To Work Certified for nearly a decade. About the PEOPLE Companies That Care List Great Place To Work selected the 2025 PEOPLE Companies that Care list by gathering and analyzing over 1.3 million confidential survey responses from companies representing more than 8.4 million U.S. employees at Great Place To Work Certified organizations. Of those, more than 1 million responses came from employees at companies eligible for the list, and these rankings are based on that feedback. Company rankings are derived from 60 employee experience questions within the Great Place To Work Trust Index ™ Survey and essays submitted by participating companies. Read the full methodology. About PEOPLE Launched in 1974, PEOPLE revolutionized personality journalism by celebrating the extraordinary in ordinary people and the ordinary in extraordinary people. Over 50 years later, it remains a trusted authority on human interest and celebrity news, reaching over 100 million consumers through digital platforms, video, social media, the PEOPLE app and print. Renowned for iconic issues such as Sexiest Man Alive and World's Most Beautiful, PEOPLE delivers breaking entertainment news, exclusive red carpet access, and in-depth reporting on today's most compelling newsmakers. With a legacy of award-winning journalism and photojournalism, PEOPLE, a brand of People Inc., is ranked No. 1 in the entertainment news category by Comscore. About Great Place To Work As the global authority on workplace culture, Great Place To Work brings 30 years of groundbreaking research and data to help every place become a great place to work for all. Its proprietary platform and Great Place To Work Model ™ help companies evaluate the experience of every employee, with exemplary workplaces becoming Great Place To Work Certified or receiving recognition on a coveted Best Workplaces ™ List. Follow Great Place To Work on LinkedIn, Twitter, and Instagram, or visit and sign up for the newsletter to learn more. About Jackson Healthcare Jackson Healthcare ® is one of the nation's premier providers of healthcare workforce services and the parent company of more than 20 businesses that share a common mission: to improve the delivery of patient care and the lives of everyone it touches. Powered by expert associates and tens of thousands of clinician providers, it delivers quality care when and where it's needed in communities across the country – helping thousands of health systems, hospitals and medical facilities serve over 20 million patients a year. Jackson Healthcare – which marks its 25 th anniversary in 2025 – is Great Place To Work ® Certified ™ and appears on the latest Forbes list of America's Top Private Companies; Fortune lists of the 100 Best Companies to Work For ® and Best Workplaces in Health Care ™; and PEOPLE ® list of Companies that Care. Learn more at
Business Wire
44 minutes ago
- Business Wire
SiriusXM's SXM-10 Satellite Successfully Begins Operational Service
NEW YORK & PALO ALTO, Calif.--(BUSINESS WIRE)--SiriusXM and Maxar Space Systems announced today that the SXM-10 satellite has completed in-orbit testing and is now fully operational by SiriusXM following its successful launch by a SpaceX Falcon 9 rocket on June 7, 2025. SXM-10 will provide continuous reliable delivery of SiriusXM's audio entertainment and information services to consumers. SXM-10 is the 11th high-powered, digital audio radio satellite built by Maxar Space Systems on the Maxar 1300™ platform. Share 'The SXM-10 satellite strengthens the health of our fleet and the infrastructure that provides a critical foundation for our audio entertainment and information services enjoyed by tens of millions of people across North America,' said Bridget Neville, SiriusXM's Senior Vice President & GM of Signal Distribution Engineering. 'The successful launch and handover of SXM-10 marks another milestone in our long-standing partnership with SiriusXM,' said Chris Johnson, CEO of Maxar Space Systems. 'This satellite reflects our shared commitment to innovation and reliability, and we are proud to be able to leverage our proven Maxar 1300™ platform to help SiriusXM deliver advanced audio entertainment services to millions of listeners.' SXM-10 will help provide continuous reliable delivery of SiriusXM's audio entertainment and information services to consumers. SXM-10 is the 11 th high-powered, digital audio radio satellite built by Maxar Space Systems for SiriusXM and is built on the Maxar 1300™ platform. SXM-10 is more than 27 feet tall and over 100 feet long with its solar arrays deployed, and weighed almost 6,600 kg at launch. SXM-10 features a large unfurlable S-band reflector antenna supplied by L3Harris that enables SiriusXM programming to reach approximately 175 million SiriusXM-equipped vehicles on the road today. SXM-10 is the second new satellite to commence service for SiriusXM in 2025 after SXM-9 began service in January. SiriusXM and Maxar Space Systems previously announced that Maxar Space has also been commissioned to build the SXM-11 and -12 satellites for SiriusXM, and those programs are ongoing with launches expected in 2026 and 2027, respectively. About Sirius XM Holdings Inc. SiriusXM is the leading audio entertainment company in North America with a portfolio of audio businesses including its flagship subscription entertainment service SiriusXM; the ad-supported and premium music streaming services of Pandora; an expansive podcast network; and a suite of business and advertising solutions. Reaching a combined monthly audience of approximately 160 million listeners, SiriusXM offers a broad range of content for listeners everywhere they tune in with a diverse mix of live, on-demand, and curated programming across music, talk, news, and sports. For more about SiriusXM, please go to: About Maxar Space Systems Maxar Space Systems is a leading satellite manufacturer and provider of advanced solutions for space exploration. We deliver innovative solutions to commercial and government customers helping them unlock the promise of space to solve problems on Earth and beyond. We address a broad spectrum of needs for our customers, including mission systems engineering, product design, spacecraft manufacturing, assembly, integration and testing. Maxar Space Systems is a trusted partner in commercial and government missions, combining more than 65 years of deep mission understanding and industry leading performance. For more information, visit This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about our outlook and our future financial and operating results, our plans, objectives, expectations and intentions with respect to future operations, products and services; and other statements identified by words such as "will likely result," "are expected to," "will continue," "is anticipated," "estimated," "believe," "intend," "plan," "projection," "outlook" or words of similar meaning or the negative version of such these words or phrases. Such forward-looking statements are based upon the current beliefs and expectations of our management and are inherently subject to significant business, economic and competitive uncertainties and contingencies, many of which are difficult to predict and generally beyond our control. Actual results and the timing of events may differ materially from the results anticipated in these forward-looking statements. The following factors, among others, could cause actual results and the timing of events to differ materially from the anticipated results or other expectations expressed in the forward-looking statements: Risks Relating to our Business and Operations: We face substantial competition and that competition has increased over time; our SiriusXM service has suffered a loss of subscribers and our Pandora ad-supported service has similarly experienced a loss of monthly active users; if our efforts to attract and retain subscribers and listeners, or convert listeners into subscribers, are not successful, our business will be adversely affected; we engage in extensive marketing efforts and the continued effectiveness of those efforts is an important part of our business; we rely on third parties for the operation of our business, and the failure of third parties to perform could adversely affect our business; failure to successfully monetize and generate revenues from podcasts and other non-music content could adversely affect our business, operating results, and financial condition; we may not realize the benefits of acquisitions or other strategic investments and initiatives; and the impact of economic conditions may adversely affect our business, operating results, and financial condition. Risks Relating to our SiriusXM Business: Changing consumer behavior and new technologies relating to our satellite radio business may reduce our subscribers and may cause our subscribers to purchase fewer services from us or to cancel our services altogether, resulting in less revenue to us; a substantial number of our SiriusXM service subscribers periodically cancel their subscriptions and we cannot predict how successful we will be at retaining customers; our ability to profitably attract and retain subscribers to our SiriusXM service is uncertain; our business depends in part upon the auto industry; the imposition of tariffs by the United States government could have a major effect on the United States auto industry, which Sirius XM is dependent upon as a material source of new subscribers; failure of our satellites would significantly damage our business; and our SiriusXM service may experience harmful interference from wireless operations. Risks Relating to our Pandora and Off-platform Business: Our Pandora and Off-platform business generates a significant portion of its revenues from advertising, and reduced spending by advertisers could harm our business; emerging industry trends may adversely impact our ability to generate revenue from advertising; our failure to convince advertisers of the benefits of our Pandora ad-supported service could harm our business; if we are unable to maintain our advertising revenue our results of operations will be adversely affected; changes to mobile operating systems and browsers may hinder our ability to sell advertising and market our services; and if we fail to accurately predict and play music, comedy or other content that our Pandora listeners enjoy, we may fail to retain existing and attract new listeners. Risks Relating to Laws and Governmental Regulations: Privacy and data security laws and regulations may hinder our ability to market our services, sell advertising and impose legal liabilities; consumer protection laws and our failure to comply with them could damage our business; failure to comply with FCC requirements could damage our business; we may face lawsuits, incur liability or suffer reputational harm as a result of content published or made available through our services; and environmental, social and governance expectations and related reporting obligations may expose us to potential liabilities, increased costs, reputational harm, and other adverse effects. Risks Associated with Data and Cybersecurity and the Protection of Consumer Information: If we fail to protect the security of personal information about our customers, we could be subject to costly government enforcement actions and private litigation and our reputation could suffer; we use artificial intelligence in our business, and challenges with properly managing its use could result in reputational harm, competitive harm, and legal liability and adversely affect our results of operations; and interruption or failure of our information technology and communications systems could impair the delivery of our service and harm our business. Risks Associated with Certain Intellectual Property Rights: Rapid technological and industry changes and new entrants could adversely impact our services; the market for music rights is changing and is subject to significant uncertainties; our Pandora services depend upon maintaining complex licenses with copyright owners, and these licenses contain onerous terms; failure to protect our intellectual property or actions by third parties to enforce their intellectual property rights could substantially harm our business and operating results; and some of our services and technologies use 'open source' software, which may restrict how we use or distribute our services or require that we release the source code subject to those licenses. Risks Related to our Capital Structure: While we currently pay a quarterly cash dividend to holders of our common stock, we may change our dividend policy at any time; our holding company structure could restrict access to funds of our subsidiaries that may be needed to pay third party obligations; we have significant indebtedness, and our subsidiaries' debt contains certain covenants that restrict their operations; and our ability to incur additional indebtedness to fund our operations could be limited, which could negatively impact our operations. Risks Related to the Transactions: We may have a significant indemnity obligation to Liberty Media, which is not limited in amount or subject to any cap, if the transactions associated with the Split-Off are treated as a taxable transaction; we may determine to forgo certain transactions that might otherwise be advantageous in order to avoid the risk of incurring significant tax-related liabilities; we have assumed and are responsible for all of the liabilities attributed to the Liberty SiriusXM Group as a result of the completion of the Transactions, and acquired the assets of SplitCo on an 'as is, where is' basis; we may be harmed by securities class action and derivative lawsuits in connection with the Transactions; it may be difficult for a third party to acquire us, even if doing so may be beneficial to our stockholders; we have directors associated with Liberty Media, which may lead to conflicting interests; and our directors and officers are protected from liability for a broad range of actions. Other Operational Risks: If we are unable to attract and retain qualified personnel, our business could be harmed; our facilities could be damaged by natural catastrophes or terrorist activities; the unfavorable outcome of pending or future litigation could have an adverse impact on our operations and financial condition; we may be exposed to liabilities that other entertainment service providers would not customarily be subject to; and our business and prospects depend on the strength of our brands. Additional factors that could cause our results to differ materially from those described in the forward-looking statements can be found in our Annual Report on Form 10-K for the year ended December 31, 2024, which is filed with the Securities and Exchange Commission (the "SEC") and available at the SEC's Internet site ( The information set forth herein speaks only as of the date hereof, and we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this communication.
